Depot medroxyprogesterone acetate: Patterns of use and reasons for discontinuation
- 31 October 1997
- journal article
- research article
- Published by Elsevier BV in Contraception
- Vol. 56 (4), 209-214
- https://doi.org/10.1016/s0010-7824(97)00140-6
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Experiences of injectable contraceptive users in an urban settingObstetrics & Gynecology, 1996
- Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraceptionContraception, 1996
- Depo‐Provera usae in an australian metropolitan practiceThe Medical Journal of Australia, 1994
- Oral contraceptives and risk of breast cancerInternational Journal of Cancer, 1990
- Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer.BMJ, 1989
- Acceptability of injectable contraceptives in Assiut, EgyptContraception, 1988
- A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100mg or 150mg: 1. Contraceptive efficacy and side effectsContraception, 1986
- Multinational comparative clinical trial of long-acting injectable contraceptives: Norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report: Who special programme of research, development and research training in human reproductionContraception, 1983
- Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. A preliminary reportContraception, 1982
- VAGINAL BLEEDING DISTURBANCES ASSOCIATED bWITH THE DISCONTINUATION OF LONG‐ACTING INJECTABLE CONTRACEPTIVESBJOG: An International Journal of Obstetrics and Gynaecology, 1981